BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 9239770)

  • 41. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context.
    Casabona G; Berton O; Singh T; Knuf M; Bonanni P
    Expert Rev Vaccines; 2023; 22(1):764-776. PubMed ID: 37642012
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
    Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
    Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children.
    Vesikari T; Ohrling A; Baer M; Delem A; Bogaerts H; André FE
    Acta Paediatr Scand; 1991 Nov; 80(11):1051-7. PubMed ID: 1661057
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children.
    Usonis V; Bakasenas V; Chitour K; Clemens R
    Infection; 1998; 26(4):222-6. PubMed ID: 9717679
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety.
    Ma SJ; Li X; Xiong YQ; Yao AL; Chen Q
    Medicine (Baltimore); 2015 Nov; 94(44):e1721. PubMed ID: 26554769
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers.
    Klein NP; Shepard J; Bedell L; Odrljin T; Dull P
    Vaccine; 2012 Jun; 30(26):3929-36. PubMed ID: 22504039
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety of a 2-dose regimen of a combined measles, mumps, rubella and varicella live vaccine manufactured with recombinant human albumin.
    Rüger G; Gabutti G; Rümke H; Rombo L; Bernaola E; Diez-Domingo J; Martinon-Torres F; Høgh B; Konstantopoulos A; Fiquet A; Thomas S; Eymin C; Baudin M
    Pediatr Infect Dis J; 2012 Nov; 31(11):1166-72. PubMed ID: 22772170
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial.
    Gillet Y; Habermehl P; Thomas S; Eymin C; Fiquet A
    BMC Med; 2009 Apr; 7():16. PubMed ID: 19366435
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.
    Macartney K; Gidding HF; Trinh L; Wang H; Dey A; Hull B; Orr K; McRae J; Richmond P; Gold M; Crawford N; Kynaston JA; McIntyre P; Wood N;
    JAMA Pediatr; 2017 Oct; 171(10):992-998. PubMed ID: 28806450
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Seroconversion of a trivalent measles, mumps, and rubella vaccine in children aged 9 and 15 months.
    Forleo-Neto E; Carvalho ES; Fuentes IC; Precivale MS; Forleo LH; Farhat CK
    Vaccine; 1997 Dec; 15(17-18):1898-901. PubMed ID: 9413099
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of immunogenicity of simultaneous and nonsimultaneous vaccination with MMR and JE vaccine among 15-month-old children.
    Tseng CY; Hwang KP; Lin KH; Chen HY; Lu CC; Chiang CH
    Acta Paediatr Taiwan; 1999; 40(3):161-5. PubMed ID: 10910607
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The immunological efficacy of the combined vaccine Trimovax intended for the prevention of measles, mumps and rubella].
    Samoĭlovich EO; Kapustik LA; Fel'dman EV; Ermolovich MA; Svirchevskaia EIu; Titov LP; Zakharenko DF; Belova EIu; Chernovetskiĭ MA; Korostik TS
    Zh Mikrobiol Epidemiol Immunobiol; 1998; (4):36-40. PubMed ID: 9783398
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Live attenuated measles, mumps, rubella, and varicella zoster virus vaccine (Priorix-Tetra).
    Dhillon S; Curran MP
    Paediatr Drugs; 2008; 10(5):337-47. PubMed ID: 18754700
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.
    Madhi SA; Koen A; Cutland C; Groome M; Santos-Lima E
    Pediatr Infect Dis J; 2013 Aug; 32(8):889-97. PubMed ID: 23538523
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A new combination vaccine for measles, mumps, rubella and varicella.
    Zareba G
    Drugs Today (Barc); 2006 May; 42(5):321-9. PubMed ID: 16801995
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.
    Blatter MM; Klein NP; Shepard JS; Leonardi M; Shapiro S; Schear M; Mufson MA; Martin JM; Varman M; Grogg S; London A; Cambron P; Douha M; Nicholson O; da Costa C; Innis BL
    Pediatr Infect Dis J; 2012 Aug; 31(8):e133-40. PubMed ID: 22622699
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Co-administration of vaccines: a focus on tetravalent Measles-Mumps-Rubella-Varicella (MMRV) and meningococcal C conjugate vaccines.
    Bonanni P; Boccalini S; Bechini A; Varone O; Matteo G; Sandri F; Gabutti G
    Hum Vaccin Immunother; 2020 Jun; 16(6):1313-1321. PubMed ID: 31810408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vaccines for measles, mumps, rubella, and varicella in children.
    Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004407. PubMed ID: 34806766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.